Year: 2022

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it plans to outline its pipeline priorities for 2023 and provide a data update for the CX-2029 Phase 2 cohort expansion study, on Thursday, January 5, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss updates. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of...

Vancouver, Dec. 22, 2022 (GLOBE NEWSWIRE) — VANCOUVER, BC, CANADA (December 22, 2022) – Victory Resources Corporation (CSE: VR) (FWB: VR61) (OTC: VRCFF) (“Victory” or the “Company”) is pleased to announce that it intends to proceed with a name change to “Victory Battery Metals Corp.” (the “Name Change”) and consolidation of its common shares on the basis of three (3) pre-consolidation common shares for one (1) post-consolidation common share of the Company (the “Share Consolidation”). The Board of Directors approved the Name Change and Share Consolidation on December 16, 2022. The Company currently has 127,611,222 common shares issued and outstanding.  Accordingly, once the Share Consolidation is effective, the Company will have 42,537,074 common shares issued and outstanding, assuming there are no other changes in the issued capital...

MURRAY, Utah, Dec. 22, 2022 (GLOBE NEWSWIRE) — R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 41st Annual J.P. Morgan Health Care Conference on Tuesday, January 10, 2023, at 7:30 am PT. A live audio webcast of the presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 30 days following the live webcast. About R1 RCM R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s...

– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company’s second clinical asset, AMT-126, in UC patients – Exploring strategic partnership options to advance AMT-101 into Phase 3 in patients with chronic pouchitis – Strong cash position of $76M reported in Q3 2022 SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced top-line Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule. The clinical remission (CR) rate...

CALGARY, Alberta, Dec. 22, 2022 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to announce the most recent version of the Company’s monthly activity update can be found on the Company’s website at https://www.petrusresources.com/monthlyupdates. ABOUT PETRUSPetrus is a public Canadian oil and gas company focused on property exploitation, strategic acquisitions and risk-managed exploration in Alberta. FOR FURTHER INFORMATION PLEASE CONTACT:Ken Gray President and Chief Executive Officer T: 403-930-0889 E: kgray@petrusresources.com

NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that it has closed a Regulation S private placement (the “Transaction”) for expected aggregate gross proceeds of $220,585. The Company currently intends to use the net proceeds from the Transaction for general working capital purposes. On December 21, 2022,  the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with 14 investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in the Transaction (i) 176,462 shares of the Company’s Series D Convertible Preferred Stock (the “Preferred...

TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) — Copper Lake Resources Ltd. (TSX-V: CPL, Frankfurt: WOI, OTC: WTCZF) (“Copper Lake” or the “Company”) is pleased to announce that it has closed the second and final tranche (the “Final Tranche”) of its non-brokered private placement offering of Flow-Through Units (the “Units”) previously announced on December 2, 2022 (the “Private Placement”). In conjunction with the closing, the Company issued an additional 6,176,472 Units for gross proceeds of $525,000, resulting in a total issuance for the Private Placement of 15,097,472 Units for gross proceeds of $1,283,285. Terr MacDonald, CEO of Copper Lake commented, “We are very pleased to have successfully raised these funds as the last few months have been very challenging for junior mining companies in the equity markets. We are now well positioned...